LBRX
NASDAQLB Pharmaceuticals Inc
News25/Ratings12
News · 26 weeks61+88%
2026-04-192026-10-11
Mix3590d
- SEC Filings13(37%)
- Other9(26%)
- Analyst5(14%)
- Insider5(14%)
- Leadership3(9%)
Latest news
25 items- PRLB Pharmaceuticals to Participate in Upcoming Investor EventsNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences: Craig-Hallum Biotech Catalyst Conference Virtual fireside chat at 10:00 a.m. ET and virtual 1x1 investor meetings on Thursday, October 22, 2026 Guggenheim Securities 3rd Annual Healthcare Innovation Conference Fireside chat at 1:00 p.m. ET and 1x1 investor meetings
- INSIDERSEC Form 4 filed by LB Pharmaceuticals Inc4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- INSIDERSEC Form 4 filed by LB Pharmaceuticals Inc4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by LB Pharmaceuticals IncSCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)
- PRLB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP CongressNEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the presentation of four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress, taking place in Munich, Germany from October 10-13, 2026. The posters highlight new preclinical data describing LB-102’s differentiated mechanism of action, the pivotal program of LB-102 in schizophrenia (NOVA-2 and NOVA-3), the ongoing late-stage development of LB-102 in bipolar depression (I
- PRLB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it has granted to Dr. Susan G. Kozauer, the new Chief Medical Officer and Joseph Miller, the new Chief Financial Officer of LB Pharmaceuticals, equity awards outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity awards were granted on October 9, 2026, pursuant to the "inducement grant" exception provided under Nasdaq Listing
- ANALYSTCanaccord Genuity initiated coverage on LB Pharmaceuticals with a new price targetCanaccord Genuity initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $65.00
- ANALYSTGuggenheim initiated coverage on LB Pharmaceuticals with a new price targetGuggenheim initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $80.00
- PRLB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia TreatmentNEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. The event will feature Roger S. McIntyre, MD, FRCPC (University of Toronto), alongside LB management team members Heather Turner (CEO), Susan G. Kozauer (CMO), Kaya Pai Panandiker (CCO), Gad Soffer (COBO), and Joe Miller (CFO), as the Company looks
- SECSEC Form EFFECT filed by LB Pharmaceuticals IncEFFECT - LB PHARMACEUTICALS INC (0001691082) (Filer)
- ANALYSTLB Pharmaceuticals downgraded by Roth Capital with a new price targetRoth Capital downgraded LB Pharmaceuticals from Buy to Neutral and set a new price target of $35.00
- ANALYSTNeedham initiated coverage on LB Pharmaceuticals with a new price targetNeedham initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $68.00
- SECSEC Form POS AM filed by LB Pharmaceuticals IncPOS AM - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form S-3ASR filed by LB Pharmaceuticals IncS-3ASR - LB PHARMACEUTICALS INC (0001691082) (Filer)
- INSIDERSEC Form 3 filed by new insider Kozauer Susan Gani3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECLB Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical OfficerNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer. Dr. Kozauer is a leader in neuropsychiatric drug development with more than two decades of development expertise spanning early-stage clinical studies through regulatory approval. She brings extensive experience across indications such as schizophrenia, mood disorders, and behavioral manifestations of neurodegenerative diseases.
- INSIDERSEC Form 3 filed by new insider Miller Joseph M3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
- PRLB Pharmaceuticals to Participate in Upcoming September Investor EventsNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team, will present and participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference 1x1 investor meetings on Wednesday, September 9, 2026, in Boston, MA H.C. Wainwright 28th Annual Global Investment Conference Presentation will be available virtually at 10:00 a.m. ET on Monday, September 14, 2026Virtual 1x1 investor m
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECLB Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
- PRLB Pharmaceuticals Appoints Joseph Miller as Chief Financial OfficerNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer. Mr. Miller is a biopharmaceutical finance executive with more than two decades of experience leading financial strategy and operations and enterprise transformation for publicly traded biotech and pharmaceutical companies. He brings a proven track record in scaling infrastructure and teams to drive organizational growth, commercializat
- SECSEC Form 424B3 filed by LB Pharmaceuticals Inc424B3 - LB PHARMACEUTICALS INC (0001691082) (Filer)
- SECSEC Form 10-Q filed by LB Pharmaceuticals Inc10-Q - LB PHARMACEUTICALS INC (0001691082) (Filer)
LBRX FAQ
6 questionsWhere does LBRX stock trade?
LB Pharmaceuticals Inc (LBRX) is listed on NASDAQ.What sector and industry is LBRX in?
LB Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did LB Pharmaceuticals Inc go public?
LB Pharmaceuticals Inc (LBRX) completed its IPO in 2025.What are analysts saying about LBRX?
LB Pharmaceuticals Inc has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-10-09. Recent price targets range from $3500.00 to $4600.00.What companies are similar to LBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LBRX side-by-side with any of them on Quantisnow.How can I track LBRX on Quantisnow?
Quantisnow aggregates LB Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LBRX to receive live email and push alerts on every new disclosure.